CTRI/2014/12/005286
已完成
未知
A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DIABOHERB IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
SBL PVT LTD0 个研究点目标入组 150 人待定
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- SBL PVT LTD
- 入组人数
- 150
- 状态
- 已完成
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Males \& Females Patients with Type 2 Diabetes Mellitus with age 30â??65 year
- •Only new cases with inadequate glucose control
- •Body mass index between 20\-35 kg/m2
- •Having fasting blood glucose \> 126 mg/dL
- •Post prandial blood glucose \> 200 mg/dL
- •Having no serious Physical abnormalities other than those generally associated with type 2 Diabetes Mellitus.
- •Patient is willing and able to comply with all trial requirements
- •Ability to understand the Informed Consent and Willing to Sign on informed consent along with audio video visual in accordance with GCP and local legislation
- •Patients able to understand and follow the protocol of the trial.
- •Participants who are able to visit the medical institutions throughout the study period
排除标准
- •Patients having Insulin dependent Diabetes Mellitus.
- •Having history of hypersensitivity, liver or kidney damage or gastrointestinal disorders, acute infections, diseases of blood or hematopoietic organs
- •Pregnant or lactating women
- •Patients receiving any concomitant medication, which may have interacted with hypoglycemic action of study drug
- •Previous participation in a clinical trial in the last 6 months.
- •Subjects who are already taking or have taken in the past 2 months any investigational drug.
- •Dehydration by clinical judgement of the investigator.
- •Any contraindication to blood sampling.
- •Severe asthma that is poorly controlled with medication.
- •Significant psychiatric illness, senility, dementia.
结局指标
主要结局
未指定
相似试验
已完成
不适用
A CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GREEN SLIM IN PATIENTS WITH OBESITY, DIABETES AND HIGH CHOLESTEROCTRI/2014/05/004635Green Chem30
进行中（未招募）
1 期
A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).EUCTR2016-002761-63-PLInovio Pharmaceuticals, Inc.198
进行中（未招募）
1 期
A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIXMedDRA version: 20.0Level: PTClassification code 10064328Term: Human papilloma virus test positiveSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.0Level: LLTClassification code 10066237Term: Cervical high grade squamous intraepithelial lesionSystem Organ Class: 100000024086Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2016-002761-63-EEInovio Pharmaceuticals, Inc.198
进行中（未招募）
1 期
A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIXMedDRA version: 21.1Level: PTClassification code 10064328Term: Human papilloma virus test positiveSystem Organ Class: 10022891 - InvestigationsMedDRA version: 21.1Level: LLTClassification code 10066237Term: Cervical high grade squamous intraepithelial lesionSystem Organ Class: 100000004872Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2016-002761-63-GBInovio Pharmaceuticals, Inc.201
进行中（未招募）
1 期
A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIXMedDRA version: 20.1Level: PTClassification code 10064328Term: Human papilloma virus test positiveSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.0Level: LLTClassification code 10066237Term: Cervical high grade squamous intraepithelial lesionSystem Organ Class: 100000004872Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2016-002761-63-CZInovio Pharmaceuticals, Inc.198